Patients treated with infliximab for inflammatory bowel disease (IBD) showed significantly reduced response to COVID-19 antibodies, compared with those treated with vedolizumab, according to data from...

NEW YORK (Reuters Health) – A subset of macrophages, PTGER4+ (EP4+), are the major drivers of epithelial regeneration after intestinal inflammation and are potential targets for inflammatory bowel...

NEW YORK (Reuters Health) – Researchers have identified the process by which adherent-invasive Escherichia coli (AIEC) bacteria drive inflammation in Crohn’s disease. They found that AIEC,...